



Taibah University

Journal of Taibah University Medical Sciences

www.sciencedirect.com



Original Article

Determining the cardiovascular effects of nitric oxide in the dorsolateral Periaqueductal Gray (dIPAG) in anaesthetised rats

Reza NejadShahrokhAbadi, MD^a, Amir Sadra Zangouei, MD^a,
Reza Mohebbati, PhD^{b, #, 1} and Mohammad Naser Shafei, PhD^{b, *}

^a Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

^b Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Received 12 May 2020; revised 1 October 2020; accepted 5 October 2020; Available online 3 November 2020



المخلص

أهداف البحث: المادة الرمادية حول القناة الظهرية الجانبية هي منطقة تقع في جذع الدماغ لديها مجموعة من الوظائف تتضمن تنظيم القلب والأوعية الدموية. نظرا لوجود أكسيد النيتريك في هذه المنطقة، تم التحقيق في تأثيرها على جهاز القلب والأوعية الدموية.

طرق البحث: تم تقسيم الفئران إلى أربع مجموعات ١- التحكم، ٢- إل-أرجينين (إل-أرجينين، هو مقدمة لأكسيد النيتريك، ٦٠ نانومول)، ٣- إل-نيم (ن اوميغا-نيترو -إل- أرجينين ميثيل استر، مثبط سينثاس أكسيد النيتريك، ٩٠ نانومول)، ٤- نيتروبروسيد الصوديوم (نيتروبروسيد الصوديوم، هو أكسيد النيتريك المانع، ٢٧ نانومول). بعد التخدير، تم تثبيت الفئران على جهاز تجسيمي وتم حقن الأدوية مجهريا في المادة الرمادية حول القناة الظهرية الجانبية. وتم تسجيل معلمات القلب والأوعية الدموية بشكل مستمر من خلال نظام مختبر الطاقة المتصل بشريان الفخذ المقنن عبر محول الضغط. كما تم حساب التغيرات في ضغط الدم الانقباضي، ومتوسط ضغط الشرايين ومعدل ضربات القلب في أوقات مختلفة مقارنة بمجموعة التحكم.

النتائج: في مجموعة إل-نيم، لم يتأثر كل من التغيرات في ضغط الدم الانقباضي، ومتوسط ضغط الشرايين ومعدل ضربات القلب بشكل ملحوظ مقارنة بمجموعة التحكم. وفي مجموعة إل- أرجينين، زاد تغير ضغط الدم الانقباضي ومتوسط ضغط الشرايين، ولكن فقط زيادة ضغط الدم الانقباضي كانت كبيرة مقارنة بمجموعة التحكم. بنما في مجموعة نيتروبروسيد الصوديوم تأثر ضغط

الدم الانقباضي ومتوسط ضغط الشرايين كثيرا مقارنة بمجموعة التحكم. بالإضافة لذلك، انخفض تغير معدل ضربات القلب في كل من مجموعة إل-أرجينين ونيتروبروسيد الصوديوم ولكن كان التغير مهما فقط في مجموعة إل-أرجينين.

الاستنتاجات: أظهرت الدراسة أن أكسيد النيتريك للمادة الرمادية حول القناة الظهرية الجانبية له تأثير ضاغط ويخفف من بطء القلب المنعكس. ومع ذلك، فإن تأثير الضغط هو أكثر أهمية.

الكلمات المفتاحية: المادة الرمادية حول القناة الظهرية الجانبية؛ إل- أرجينين؛ إل-نيم؛ نيتروبروسيد الصوديوم؛ ضغط الدم؛ معلمات القلب والأوعية الدموية

Abstract

Objective: The dorsolateral periaqueductal gray (dIPAG) is an area located in the brain stem that performs a host of functions including cardiovascular regulation. Owing to the presence of nitric oxide (NO) in this area, we investigated its effect on the cardiovascular system.

Methods: We divided rats into four groups: 1) control; 2) L-arginine (L-Arg, a precursor for nitric oxide, 60 nmol); 3) L-NAME (N omega-nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor, 90 nmol); and 4) sodium nitroprusside (SNP, a nitric oxide donor, 27 nmol). After anaesthesia, the rats were mounted on a stereotaxic apparatus and the drugs were microinjected into the dIPAG. Cardiovascular parameters were continuously recorded by a PowerLab system connected to the cannulated femoral artery via a pressure transducer. The changes (Δ) of systolic blood pressure (SBP), mean arterial pressure (MAP), and heart rate (HR) were calculated at different times as compared to the control group.

* Corresponding address: Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences (MUMS), Pardis, Vakilabad Street, Mashhad, 9177948564, Iran.

E-mail: Shafeimn@mums.ac.ir (M.N. Shafei)

Peer review under responsibility of Taibah University.



Production and hosting by Elsevier

Co-first author.

¹ Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

1658-3612 © 2020 The Authors.

Production and hosting by Elsevier Ltd on behalf of Taibah University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). <https://doi.org/10.1016/j.jtumed.2020.10.004>

Results: In the L-NAME group, the Δ SBP, Δ MAP, and Δ HR were not significantly affected compared to the control group. In the L-Arg group, Δ SBP and Δ MAP increased; however, only SBP showed a significant increase compared to the control group. In the SNP group, SBP and MAP were significantly affected in comparison to the controls. Additionally, Δ HR decreased in both L-Arg and SNP, but was only significant in L-Arg.

Conclusion: Our study showed that NO of dIPAG has a pressor effect and attenuates baroreflex bradycardia. However, its pressor effect is more significant.

Keywords: Blood pressure; Cardiovascular parameters; Dorsolateral periaqueductal gray; L-arginine; L-NAME; Sodium nitroprusside

© 2020 The Authors.

Production and hosting by Elsevier Ltd on behalf of Taibah University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The dorsolateral periaqueductal gray (dIPAG) is a mesencephalic area located around the cerebral aqueduct.¹ This area is mainly involved in defence responses and stress mechanisms. The dIPAG has connections to numerous parts of the brain including the cortex, hypothalamus, and spinal cord.² The dIPAG also has bidirectional connections to the hypothalamus nuclei,³ such as the dorsomedial hypothalamus (DMH),⁴ especially with its rostral segment.⁵ This area also has a major projection to the cuneiform nucleus (CnF).³

Nitric oxide (NO) is a highly soluble gas, which acts as an important neurotransmitter in the brain. It mediates the production of cyclic guanosine monophosphate (cGMP) through the activation of the enzyme guanylate cyclase. NO is synthesised by the enzyme nitric oxide synthase (NOS), which has three isoforms (eNOS, iNOS, and nNOS),⁶ and has been found in cardiovascular control centres.^{7,8} NOS catalyses a reaction, in which the amino acid L-arginine (L-Arg) acts as a precursor, resulting in the release of citrulline and NO.⁹

Nitric oxide is an essential neurotransmitter in the dIPAG and is involved in the modulation of autonomic responses during defence responses and stress. Its interaction with the GABAergic and glutamatergic systems of dIPAG has previously been determined to increase miniature inhibitory post-synaptic currents in all neurons.¹⁰ Additionally, NO has also been identified as an important neurotransmitter in other parts of the rat brain such as the rostral ventrolateral medulla (RVLM) nucleus,¹¹ which plays an essential role in cardiovascular function.^{12,13} Microinjection of a NO donor into RVLM significantly decreased the blood pressure, while the inhibition of NOS increased it.^{7,14} Such inhibitory effects of NO on the cardiovascular system have also been documented in both CnF¹⁵ and pedunculopontine tegmental (PPT) nuclei.¹⁶ Inhibition of

NOS in the paraventricular nucleus (PVN) increased blood pressure and heart rate, which were attenuated by L-Arg.¹⁷ In the dIPAG, NO has also been shown to attenuate the cardiovascular effects of glutamate during thermal and mechanical stimulation.¹⁸ Since NO present in the dIPAG is an important neurotransmitter in the brain that exerts central cardiovascular effects via interactions with numerous neurotransmitters, this study is an initiative to investigate the possible role of NO in the dIPAG on the cardiovascular system.

Materials and Methods

Animals

Twenty male Wistar rats weighing 240 ± 20 g were used in this experiment. The animals were maintained under a 12:12 h light–dark cycle and had free access to food and water.

Selection of drugs

The drugs used in this study were urethane (anaesthesia), L-Arg (an NO precursor), NG-nitro-L-arginine methyl ester (L-NAME, a nitric oxide synthase inhibitor), and sodium nitroprusside (SNP, an NO donor). All drugs used in this experiment were procured from Sigma, USA.

Experiment groups

Rats were divided into four groups based on different drug microinjections administered, as follows: 1) Control group (n = 5): Microinjection of saline into the dIPAG; 2) L-Arg group (n = 5): Microinjection of L-Arg (60 nmol¹⁵) into the dIPAG; 3) L-NAME group (n = 5): Microinjection of L-NAME (90 nmol¹⁵) into the dIPAG; 4) SNP group (n = 5): Microinjection of SNP (27 nmol¹⁵) into the dIPAG. Volume injection was 100–150 nl in all groups.

Experiment protocol

The rats were anaesthetised before the experiment with urethane (1.4 g/kg, ip).¹⁹ The left femoral artery was then cannulated using a blue angiocath filled with heparinised saline. This angiocath was connected to a PowerLab system (ADInstruments, Bella Vista, NSW, Australia) via a pressure transducer to record cardiovascular parameters.²⁰ For microinjection of the drugs, the rats were mounted on a stereotaxic apparatus, and the skull was surgically exposed. A hole was then drilled through the skull directly over the dIPAG in accordance with the rat brain atlas of Paxinos and Watson (AP: 6.8 mm caudal to bregma, L: 0.7 mm lateral to the midline; H: 5 mm).²¹ After a stabilising period (10 min), the drugs were microinjected, and cardiovascular responses were recorded continuously for 15 min thereafter.

Statistical analysis

The cardiovascular parameters were recorded before and after the injections. A trend of change (Δ) in the systolic

blood pressure (Δ SBP), mean arterial pressure (Δ MAP) and heart rate (Δ HR) was obtained before, and 5, 10, and 15 min after drug injection and compared with the control group. The data were expressed as the mean \pm SEM and comparisons were performed by repeated measures of analysis of variance (ANOVA) (GraphPad InStat version 3.10), and a P-value of <0.05 indicated significance.

Histological analysis

After the experiment, the rats were sacrificed under urethane (1.5 g/kg, i.p) anaesthesia, their brains were removed, and stored in a 10% formalin solution for at least 48 h. Serial sections (60 μ m) were then obtained using a vibrator microtome. The injection site was observed under a light microscope, and the injection site was verified according to the Paxinos and Watson rat brain atlas (Figure 1).²²

Results

Cardiovascular responses evoked after microinjection of saline into the dIPAG

In this experiment, saline was microinjected into the dIPAG. The recorded baseline values for HR, SBP, and MAP were 340 ± 8 beats/min, 130 ± 5 mmHg, and 110 ± 3 mmHg, respectively. After the microinjection of saline, these parameters were recorded as follows: Δ HR: 351 ± 10 beats/min, Δ SBP: 136 ± 6.5 mmHg, and Δ MAP: 115 ± 4.9 mmHg, which were not significant compared to pre-injection.

Cardiovascular responses evoked after microinjection of L-Arg into the dIPAG

When L-Arg was microinjected into the dIPAG, the SBP and MAP increased, whereas HR decreased (Figure 2A and B). Time-course changes in cardiovascular responses are indicated in Figure 3A and B. Increase in Δ SBP and Δ MAP were significant compared to the control over time ($P < 0.05$,

repeated measures ANOVA). Peak changes in Δ SBP and Δ MAP were also significant compared to that in the control ($P < 0.01$ and $P < 0.05$, respectively; Figure 3A and B). The Δ HR was not significant compared to the control group over time; however, the peak change was significant compared to the control group ($P < 0.05$; Figure 3C).

Cardiovascular responses evoked after microinjection of L-NAME into the dIPAG

When L-NAME was microinjected into the dIPAG, the SBP, MAP, and HR slightly increased. As shown in Figures 3 and 4, time-course changes in all responses were not significant when compared to the control over time. Moreover, peak changes in all parameters were not significant with respect to the saline group.

Cardiovascular responses evoked after microinjection of SNP into the dIPAG

Microinjection of SNP into the dIPAG increased SBP and MAP but decreased HR (Figure 4 C). Time-course changes showed that Δ SBP and Δ MAP significantly increased over time ($P < 0.001$ - $P < 0.01$, respectively; Figure 3A and B). Peak changes in Δ SBP and Δ MAP also significantly increased compared to those of the control groups ($P < 0.001$; Figure 4A and B). The mean changes of Δ HR were not significant when compared to that of the control group over time (Figure 3C). The peak change in Δ HR was not significant with respect to the control group (Figure 4C).

Comparison of peak changes in cardiovascular responses in the experimental groups

The MAP and SBP increased after microinjection of SNP and L-Arg into dIPAG; however, the microinjection of L-NAME had no significant effect (Figure 2). As has been shown in Figure 3A and B, peak changes in SBP




Figure 1: Sample of brain section after microinjection of the drug into the dIPAG (A). Coordinates of injection adopted from the Paxinos atlas (B).




Figure 2: Recorded samples of the changes after microinjection of L-Arg (A), L-NAME (B), and SNP (C) into the dIPAG. PBP, pulsative blood pressure; MAP, mean arterial pressure; HR, heart rate.

and MAP in the SNP group were significant compared to the L-Arg ($P < 0.05$ to $P < 0.001$, respectively) and L-NAME groups ($P < 0.01$ in both parameters). Peak Δ SBP and Δ MAP in the L-Arg group were not significant compared to those in the L-NAME group. The HR in the L-NAME group increased but those in the L-

Arg and SNP groups decreased (Figure 2C). As shown in Figure 4, peak Δ HR in the L-NAME group was significant compared to that of SNP ($P < 0.01$) and L-Arg ($P < 0.05$) groups. Moreover, there was no significant difference between the peak changes of L-Arg and SNP groups (Figure 4C).




Figure 3: Time-course for changes in systolic blood pressure (Δ SBP) (A), mean arterial pressure (Δ MAP) (B) and heart rate (Δ HR) (C) following the injection L-NAME, SNP, and L-Arg into the dIPAG. Δ SBP and Δ MAP only in L-Arg ($P < 0.05$) and SNP ($P < 0.001$ and $P < 0.01$, respectively) significantly increased compared to control over time. In all groups, Δ HR was not significant than control over time. No significance was found for microinjection with L-NAME when compared to control. Statistical analysis: Repeated measures ANOVA; $n = 5$. L-NAME: N^G -nitro-L-arginine methyl ester; a NOS inhibitor, L-Arg: L- Arginine, a NO precursor, SNP: sodium nitroprusside, a NO donor.




Figure 4: Peak changes in systolic blood pressure (Δ SBP) (A), mean arterial pressure (Δ MAP) (B), and heart rate (Δ HR) (C), after microinjection of L-NAME, SNP, and L-Arg into the dIPAG in separate groups. Statistical analysis: One-way ANOVA, followed by Tukey's post hoc test; $n = 5$. *: $P < 0.05$, **: $P < 0.01$, and ***: $P < 0.001$ (vs. control). +: $P < 0.05$, ++: $P < 0.01$, and +++: $P < 0.001$ (vs. L-NAME). # $P < 0.05$ (comparison of L-Arg and SNP, significant for Δ SBP and Δ MAP).

Discussion

The results showed that both SNP (a NO donor) and L-Arg (a NO precursor), when microinjected into the dIPAG, increased SBP and MAP, while L-NAME had no significant effect on these parameters. Only L-Arg had a significant effect on HR.

This study shows that NO in the dIPAG is involved in cardiovascular regulation, and this effect contrasts the cardiovascular effect of NO in other areas of the brain such as the RVLM, CnF, and PPT.^{14–16} The effects of L-Arg confirmed the presence of NOS enzyme in the dIPAG, in accordance with previous studies.^{23–25} In addition, the cardiovascular effects of both SNP and L-Arg showed the existence of NO receptors within the dIPAG in accordance with previous experiments.^{10,26}

In this study, the microinjection of L-NAME did not significantly change the cardiovascular parameters. A possible explanation is that there is no substrate for the enzyme to utilise; therefore, it produces no effect when inhibited. Based on these results, we suggested that in anaesthetised rats, the substrate for NOS was not available in the dIPAG, and therefore NO was not synthesised.

The mechanism for the cardiovascular effect of NO in the dIPAG is unknown, and is suggested to be the result of projections from this area to various other regions involved in cardiovascular regulation. Direct projections from dIPAG to RVLM, an essential area for cardiovascular regulation, have not been reported, and indirect projections are possibly involved in this effect. The dIPAG has two principal projections to the CnF²⁷ and lateral parabrachial subnucleus (LPB).²⁸ A minor projection to the DMH nucleus of the hypothalamus also exists.^{4,5} These connections project to the RVLM, and probably precipitate the cardiovascular control of dIPAG.²⁹ One important projection of dIPAG is to the CnF.²⁹ The CnF is a sympathoexcitatory area that, via its glutamatergic neurons, can evoke cardiovascular responses.¹⁹ We suggest the presence of an excitatory projection from dIPAG to CnF, which, through NO, increases blood pressure.

Another projection of dIPAG is to the PB complex. This area comprises 13 subnuclei, including the lateral parabrachial nucleus (IPB),³⁰ to which the dIPAG exclusively projects.²⁸ Previous experiments have shown that a stimulation of the IPB by glutamate increases blood pressure.³¹ We suggest that this pathway also precipitates in the cardiovascular effect of

NO. The dIPAG also projects to the DMH, both directly and indirectly through the CnF³² and superior lateral BP nucleus.³⁰ The DMH has connections to various other nuclei containing sympathetic outflow neurons, including the RVLM³³ and the raphe pallidus.³⁴ It has also been shown that the activation or disinhibition of the DMH provokes an excitatory cardiovascular response.³⁵

In the dIPAG nucleus, NO is shown to act as an inhibitory neurotransmitter, acting on the GABAergic system via pre-synaptic sites, which facilitates the release of GABA and suppresses the neuronal activity within the nucleus.²⁹ However, our results showed that L-Arg and SNP increased blood pressure. The mechanism(s) of this opposite effect has not been determined. However, it has been reported that NO donors in the PAG could increase both excitatory and inhibitory synapses that could have a different effect on neuronal populations.³⁶ The dIPAG has many neurons including excitatory (glutamatergic neurons) and inhibitory (GABAergic neurons)^{2,37}; therefore, the interaction of NO with these neuronal population may explain this contradictory effect.

The NOS has three isoforms (eNOS, iNOS, and nNOS), and the effects of each isoform are different. For example, in RVLM, NO synthesised by nNOS causes sympathoexcitation via glutamate receptors, and NO driven by iNOS have been shown sympathoinhibition via GABA receptors.³⁸ We suggest that the dIPAG also has different isoforms of NOS, and its excitatory effect is higher than the inhibitory effect. In support of this opinion, the dIPAG is involved in autonomic responses during stress, during which, the expression of nNOS in dIPAG is increased.³⁹ Based on these results, the increase in nNOS induced by L-Arg and SNP could increase blood pressure. However, further studies are needed to confirm this hypothesis.

In addition, our results indicated that L-NAME slightly increased HR; however, SNP and L-Arg decreased HR. This bradycardia may be mediated by baroreflex activity. In our results, bradycardia after microinjection of L-Arg was higher than that after SNP microinjection, while the effect of SNP on blood pressure was higher than that of L-Arg. We suggest that NO within the dIPAG may attenuate baroreflex bradycardia in response to elevated blood pressure. Moreover, since SNP induced a stronger response, baroreflex was highly inhibited, which led to a reduction in the heart rate. This effect is possibly due to the NTS, by way of the CnF nucleus.⁴⁰ The dIPAG is a critical area involved in autonomic

responses in stress and defence responses. These responses are mediated by the interaction of several neurotransmitters. Therefore, the effect of NO alone may differ when several neurotransmitters interact with each other. Thus, we propose that future studies focus on the interaction of NO with other neurotransmitters.

An important strength of this study is the investigation of all aspects of NO in the nucleus. There are some limitations to this current study. First, we did not investigate the baroreflex sensitivity. Second, we did not perform bilateral microinjection due to stereotaxic limitations. Third, we did not focus on other neurotransmitters and their roles in cardiovascular responses. We hope that future studies in this area address these limitations.

Conclusion

In summary, direct microinjection SNP and L-Arg significantly increased MAP and SBP blood pressure, while L-NAME had no significant effect on any recorded parameter. In addition, HR was decreased by SNP and L-Arg microinjection, and this effect was only significant in the L-Arg group.

The current results indicate that NO synthesis in the dIPAG produces pressor responses and attenuates baroreflex bradycardia, but its pressor effect is more significant.

Source of funding

The authors thank the Research Council of Mashhad University of Medical Sciences for providing the infrastructure and facilities for this research.

Conflict of interest

The authors have no conflict of interest to declare.

Ethical approval

All experimental procedures were approved by the ethical committee of Mashhad University of Medical Sciences (IR.MUMS.MEDICAL.REC.1398.248, dated 09 April 2019).

Authors contributions

MNS and RM conceived and designed the study, conducted experiments, provided research materials, and collected and organised the data. RM and RNSA analysed and interpreted the data. ASZ and RNSA wrote the initial and final draft of the article and provided logistic support. All authors have critically reviewed and approved the final draft and are responsible for the content and similarity index of the manuscript.

Acknowledgment

We would like to thank the Vice Chancellor for Research, Mashhad University of Medical Sciences, Mashhad, Iran (Grant No: 971516) for his financial support.

References

1. Bandler R, Shipley MT. Columnar organization in the midbrain periaqueductal gray: modules for emotional expression? *Trends Neurosci* **1994**; 17: 379–389.
2. Dampney RaL, Furlong TM, Horiuchi J, Iigaya K. Role of dorsolateral periaqueductal grey in the coordinated regulation of cardiovascular and respiratory function. *Auton Neurosci* **2013**; 175: 17–25.
3. Vianna D, Brandao M. Anatomical connections of the periaqueductal gray: specific neural substrates for different kinds of fear. *Braz J Med Biol Res* **2003**; 36: 557–566.
4. Thompson RH, Swanson LW. Organization of inputs to the dorsomedial nucleus of the hypothalamus: a reexamination with Fluorogold and PHAL in the rat. *Brain Res Brain Res Rev* **1998**; 27: 89–118.
5. Cameron AA, Khan IA, Westlund KN, Cliffer KD, Willis WD. The efferent projections of the periaqueductal gray in the rat: a Phaseolus vulgaris-leucoagglutinin study. I. Ascending projections. *J Comp Neurol* **1995**; 351: 568–584.
6. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. *Biochem J* **2001**; 357: 593–615.
7. Kagiya S, Tsuchihashi T, Abe I, Fujishima M. Cardiovascular effects of nitric oxide in the rostral ventrolateral medulla of rats. *Brain Res* **1997**; 757: 155–158.
8. Patel KP, Li Y-F, Hirooka Y. Role of nitric oxide in central sympathetic outflow. *Exp Biol Med* **2001**; 226: 814–824.
9. Knowles RG, Moncada S. Nitric oxide synthases in mammals. *Biochem J* **1994**; 298(Pt 2): 249–258.
10. Xing J, Li D-P, Li J. Role of GABA receptors in nitric oxide inhibition of dorsolateral periaqueductal gray neurons. *Neuropharmacology* **2008**; 54: 734–744.
11. Chan SH, Wang LL, Wang SH, Chan JY. Differential cardiovascular responses to blockade of nNOS or iNOS in rostral ventrolateral medulla of the rat. *Br J Pharmacol* **2001**; 133: 606–614.
12. Dampney RA. Functional organization of central pathways regulating the cardiovascular system. *Physiol Rev* **1994**; 74: 323–364.
13. Dampney RaL, Horiuchi J. Functional organisation of central cardiovascular pathways: studies using c-fos gene expression. *Prog Neurobiol (Oxf)* **2003**; 71: 359–384.
14. Zanzinger J, Czachurski J, Seller H. Inhibition of basal and reflex-mediated sympathetic activity in the RVLM by nitric oxide. *Am J Physiol Regul Integr Comp Physiol* **1995**; 268: 958–962.
15. Farrokhi E, Shafei MN, Khajavirad A, Hosseini M, Bideskan ARE. Role of the nitrenergic system of the cuneiform nucleus in cardiovascular responses in urethane-anesthetized male rats. *Iran J Med Sci* **2017**; 42: 473–480.
16. Shafei MN, Nikyar T, Hosseini M, Niazmand S, Paseban M. Cardiovascular effects of nitrenergic system of the pedunculo-pontine tegmental nucleus in anesthetized rats. *Iran J Basic Med Sci* **2017**; 20: 776–782.
17. Zhang K, Mayhan WG, Patel KP. Nitric oxide within the paraventricular nucleus mediates changes in renal sympathetic nerve activity. *Am J Physiol Regul Integr Comp Physiol* **1997**; 273: 864–872.
18. Ishide T, Amer A, Maher TJ, Ally A. Nitric oxide within periaqueductal gray modulates glutamatergic neurotransmission and cardiovascular responses during mechanical and thermal stimuli. *Neurosci Res* **2005**; 51: 93–103.
19. Shafei MN, Nasimi A. Effect of glutamate stimulation of the cuneiform nucleus on cardiovascular regulation in anesthetized rats: role of the pontine Kolliker–Fuse nucleus. *Brain Res* **2011**; 1385: 135–143.

20. Mohebbati R, Hosseini M, Khazaei M, Khajavirad A, Shafei MN. The effects of inactivation of pedunculopontine tegmental nucleus by cobalt (II) chloride on cardiovascular responses in hemorrhagic hypotensive rats. **Basic Clin Neurosci** 2019; 10: 235–244.
21. Paxinos G, Watson C. *The rat brain in stereotaxic coordinates: hard*. cover edition. Elsevier; 2006.
22. Shafei MN, Niazmand S, Hosseini M, Daloe MH. Pharmacological study of cholinergic system on cardiovascular regulation in the cuneiform nucleus of rat. **Neurosci Lett** 2013; 549: 12–17.
23. De Oliveira RMW, Aparecida Del Bel E, Mamede-Rosa MLN, Padovan CM, Deakin JFW, Guimarães FS. Expression of neuronal nitric oxide synthase mRNA in stress-related brain areas after restraint in rats. **Neurosci Lett** 2000; 289: 123–126.
24. Guimarães FS, Bejjamini V, Moreira FA, Aguiar DC, De Lucca ACB. Role of nitric oxide in brain regions related to defensive reactions. **Neurosci Biobehav Rev** 2005; 29: 1313–1322.
25. Chaitoff KA, Patel D, Ally A. Effects of endothelial NOS antagonism within the periaqueductal gray on cardiovascular responses and neurotransmission during mechanical, heat, and cold nociception. **Brain Res** 2008; 1236: 93–104.
26. De Oliveira RMW, Del Bel EA, Guimarães FS. Effects of excitatory amino acids and nitric oxide on flight behavior elicited from the dorsolateral periaqueductal gray. **Neurosci Biobehav Rev** 2001; 25: 679–685.
27. Bernard JF, Peschanski M, Besson JM. Afferents and efferents of the rat cuneiformis nucleus: an anatomical study with reference to pain transmission. **Brain Res** 1989; 490: 181–185.
28. Krout KE, Jansen AS, Loewy AD. Periaqueductal gray matter projection to the parabrachial nucleus in rat. **J Comp Neurol** 1998; 401: 437–454.
29. Dampney RA, Furlong TM, Horiuchi J, Iigaya K. Role of dorsolateral periaqueductal grey in the coordinated regulation of cardiovascular and respiratory function. **Auton Neurosci** 2013; 175: 17–25.
30. Fulwiler CE, Saper CB. Subnuclear organization of the efferent connections of the parabrachial nucleus in the rat. **Brain Res** 1984; 319: 229–259.
31. Lara JP, Parkes MJ, Silva-Carvalho L, Izzo P, Dawid-Milner MS, Spyer KM. Cardiovascular and respiratory effects of stimulation of cell bodies of the parabrachial nuclei in the anaesthetized rat. **J Physiol** 1994; 477: 321–329.
32. Lam W, Gundlach AL, Verberne AJ. Neuronal activation in the forebrain following electrical stimulation of the cuneiform nucleus in the rat: hypothalamic expression of c-fos and NGFI-A messenger RNA. **Neuroscience** 1997; 78: 1069–1085.
33. Fontes M, Tagawa T, Polson J, Cavanagh S-J, Dampney R. Descending pathways mediating cardiovascular response from dorsomedial hypothalamic nucleus. **Am J Physiol Heart Circ Physiol** 2001; 280: 2891–2901.
34. Samuels BC, Zaretsky DV, Dimicco JA. Dorsomedial hypothalamic sites where disinhibition evokes tachycardia correlate with location of raphe-projecting neurons. **Am J Physiol Regul Integr Comp Physiol** 2004; 287: 472–478.
35. Da Silva Jr LG, Alvim De Menezes RC, Souza Dos Santos RA, Campagnole-Santos MJ, Peliky Fontes MA. Role of periaqueductal gray on the cardiovascular response evoked by disinhibition of the dorsomedial hypothalamus. **Brain Res** 2003; 984: 206–214.
36. De Oliveira R, Del Bel E, Guimaraes F. Effects of excitatory amino acids and nitric oxide on flight behavior elicited from the dorsolateral periaqueductal gray. **Neurosci Biobehav Rev** 2001; 25: 679–685.
37. Moreira FA, Molchanov ML, Guimarães FS. Ionotropic glutamate-receptor antagonists inhibit the aversive effects of nitric oxide donor injected into the dorsolateral periaqueductal gray of rats. **Psychopharmacol** 2004; 171: 199–203.
38. Martins-Pinge MC, Garcia MR, Zoccal DB, Crestani CC, Pingue-Filho P. Differential influence of iNOS and nNOS inhibitors on rostral ventrolateral medullary mediated cardiovascular control in conscious rats. **Auton Neurosci** 2007; 131: 65–69.
39. De Oliveira RMW, Del Bel EA, Mamede-Rosa MLN, Padovan CM, Deakin JFW, Guimarães FS. Expression of neuronal nitric oxide synthase mRNA in stress-related brain areas after restraint in rats. **Neurosci Lett** 2000; 289: 123–126.
40. Korte SM, Jaarsma D, Luiten PGM, Bohus B. Mesencephalic cuneiform nucleus and its ascending and descending projections serve stress-related cardiovascular responses in the rat. **J Auton Nerv Syst** 1992; 41: 157–176.

How to cite this article: NejadShahrokhAbadi R, Zangouei AS, Mohebbati R, Shafei MN. Determining the cardiovascular effects of nitric oxide in the dorsolateral Periaqueductal Gray (dIPAG) in anaesthetised rats. *J Taibah Univ Med Sc* 2020;15(6):502–508.